RACHEAL ANEKE: Open Payments
NPI 1073071684 · FOLSOM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,740 in 70 payments from 15 companies in 2025. Trend: 2023 $526 · 2024 $1,110 · 2025 $1,740
Food & beverage: $1,629Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $366 |
| Otsuka America Pharmaceutical, Inc. | 12 | $323 |
| Neurocrine BioSciences, Inc. | 11 | $322 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $189 |
| E.R. Squibb & Sons, L.L.C. | 7 | $176 |
| Janssen Pharmaceuticals, Inc | 3 | $153 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Supernus Pharmaceuticals, Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $21 |
Products named: INGREZZA, CAPLYTA, COBENFY, UZEDY, INVEGA SUSTENNA, REXULTI, ABILIFY MAINTENA, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
